For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() CVS Health CorporationCVS US · Health Care · USD Current price$80.04as of Nov 20, 2026 Summary
Analyst consensusStrong Buy 7Buy 18Hold 326 analysts 3-year price (USD)Factor profileMulti-factor score 90 / 100 Market data
Business descriptionLargest U.S. pharmacy health care provider: CVS Pharmacy (retail), CVS Caremark (PBM), Aetna (health insurance, with a sizeable Medicare Advantage book), Oak Street (primary care) and Signify (in-home health). Sub-industry: Health Care Services; S&P 500, Large-Cap Value. Competitive moatVertical integration (pharmacy footprint, Caremark PBM scale, Aetna, owned care delivery) gives data and channel control few peers can match. The same breadth is also the regulatory lightning rod (PBM scrutiny, Aetna ownership). Recent developments
Investment risks / red flags
Financials
Classification
|
Last updated: Nov 13, 2026
Current price: $80.04 · Nov 20, 2026· USD
CFRA Ratingbuy
TBI Multi Score90
Loading graph…
Factor Profile (Spider Chart)
TBI ModelPrice Chart (TradingView)
Symbol: CVSBusiness description
Largest U.S. pharmacy health care provider: CVS Pharmacy (retail), CVS Caremark (PBM), Aetna (health insurance, with a sizeable Medicare Advantage book), Oak Street (primary care) and Signify (in-home health). Sub-industry: Health Care Services; S&P 500, Large-Cap Value.
Competitive moat
Vertical integration (pharmacy footprint, Caremark PBM scale, Aetna, owned care delivery) gives data and channel control few peers can match. The same breadth is also the regulatory lightning rod (PBM scrutiny, Aetna ownership).
Recent developments
- Q3 2026 (11/04/2026): EPS beat; Health Care Benefits adjusted operating income up nearly USD 600M Y/Y, MBR improved about 150 bps to 91.3%; Medicare Advantage back to profitability ahead of schedule; target leverage reached, buybacks resume in Q4. Management targets the high end of the mid-teens adjusted EPS CAGR through 2028.
- Breakup (11/04/2026): plan to split into CVS Pharmacy (retail) and CVS Health (Caremark, Aetna, Oak Street, Signify; CEO Joyner) via a tax-free spin by 1H 2028. Shares sold off sharply; CFRA reads it partly as a response to likely regulatory pressure on drug prices after the midterms.
- Retail stabilizing: long-term Pharmacy and Consumer Wellness growth now at least flat (previously 5% annual declines); GLP-1 scripts +23% Y/Y, same-store Rx +3.9%.
- Policy: 2027 MA final rate notice +2.48%; Stars reform worth about USD 5B to MA insurers in 2028; over 69% of Aetna MA members in 4+ star plans. Sector context: Managed Health Care Q3 2026 Earnings & Post-Midterm Policy.
Investment risks / red flags
- Caremark membership declines expected in 2027; Health Services (340B pressure) guided to trough earnings in 2027.
- Elevated MA utilization and MBR volatility; PBM and drug-pricing legislation.
- Separation execution: stranded costs, dis-synergies, uncertainty on standalone prospects.
- Relative strength rank weak (24/99).
Market Data
Source: mkts.io · Nov 20, 2026, 14:01 UTC
Key Metrics
P/E (TTM)9.30
P/E (Fwd)9.20
Dividend3.32%
Beta0.58
52W High$110.68
52W Low$69.51
Analyst Consensus
7
18
3
Strong Buy7Buy18Hold326 analysts
Consensus Target$109.31
+36.6% upside
Calendar Events
Next EarningsNov 4, 2026
Ex-DividendOct 22, 2026
Dividend DateNov 2, 2026
Financials
Revenue$418.16B
Rev Growth5.40%
Gross Margin13.72%
Op Margin3.06%
Profit Margin2.64%
EBITDA$17.29B
ROA3.11%
ROE14.36%
Rev/Share$327.71
Total Cash$14.89B
Total Debt$75.30B
D/E Ratio93.32
Free Cash Flow$11.83B
Op Cash Flow$18.71B
Current Ratio0.85
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 1.05 | $107.62B |
| +1q | 2.74 | $102.33B |
| 0y | 8.28 | $422.04B |
| +1y | 8.70 | $431.42B |
Earnings
Quarterly EPS
4Q2025
Est: 1.001.09Beat
1Q2026
Est: 2.212.57Beat
2Q2026
Est: 1.852.58Beat
3Q2026
Est: 1.652.09Beat
Annual
2022
Rev $322.47BEarn $4.15B
2023
Rev $357.78BEarn $8.34B
2024
Rev $372.81BEarn $4.61B
2025
Rev $402.07BEarn $1.77B
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Nov 12, 2026 | Wells Fargo | main | Overweight |
| Nov 6, 2026 | UBS | main | Buy |
| Nov 5, 2026 | Leerink Partners | main | Outperform |
| Nov 5, 2026 | Barclays | main | Overweight |
| Oct 12, 2026 | Leerink Partners | main | Outperform |
| Sep 3, 2026 | UBS | main | Buy |
